Clinical trial
A Phase II Trial of MRD (Melphalan, Lenalidomide and Dexamethasone) for Patients With AL Amyloidosis
NCT00679367 is registered in ClinicalTrials.gov with Boston Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of MRD (Melphalan, Lenalidomide and Dexamethasone) for Patients With AL Amyloidosis
- Lead sponsor
- Boston Medical Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2008
- Completion date
- May 31, 2015
- Enrollment
- 16 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.